MYC and pancreatic ductal adenocarcinoma: Researchers detected coexpression of MYC and SUMO-related factors (such as SAE1, UBC9, SUMO1, SUMO2/3) in Pancreatic ductal adenocarcinoma (PDAC), and hyperactivation of MYC was associated with increased sensitivity to pharmacological SUMO inhibition, which provided a new therapeutic strategy to PDAC [59].